| Project/Area Number |
24590896
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General internal medicine (including Psychosomatic medicine)
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HYUGA Sumiko 北里大学, 東洋医学総合研究所, 室長補佐 (60353471)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HYUGA Masashi 国立医薬品食品衛生研究所, 主任研究官 (50251658)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 漢方薬 / 麻黄 / 薬剤耐性肺がん / エルロチニブ / Met / EGFR / MET阻害剤 / 非小細胞肺がん / 耐性 / EGFR-TKI / MET / 麻黄湯 / 分子標的治療薬 |
|---|
| Outline of Final Research Achievements |
The EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib have shown marked therapeutic effects against non-small-cell lung cancer with activated EGFR. However, almost the tumors acquire resistance to EGFR-TKIs after a few years. One of the mechanisms for acquired resistance is Met gene amplification. The combination of EGFR-TKI and Met inhibitor is considered to be effective against the EGFR-TKI resistant tumor, but the Met inhibitors have not yet been pharmaceuticals. We have previously clarified that Ephedra herb, a component of kampo medicines, inhibits the tyrosine phosphorylation of Met. In this study, we revealed that the combination of erlotinib and Ephedra herb prevented the growth of the EGFR-TKI resistant non-small-cell lung cancer H1993 cells in vitro and in vivo. Furthermore, we found that Ephedra herb reduced the expression levels of both Met and EGFR in H1993 cells.
|
